Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C

Hepatology

Volumn 38, Issue 1, 2003, Pages 75-85

  Poynard, Thierry ^a   Ratziu, Vlad ^a   McHutchison, John ^b   Manns, Michael ^c   Goodman, Zachary ^d   Zeuzem, Stefan ^e   Younossi, Zobair ^f   Albrecht, Janice ^g  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^e SAARLAND UNIVERSITY   (Germany)

^f INOVA FAIRFAX HOSPITAL   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CHOLESTEROL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATTY LIVER; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; VIRUS LOAD; VIRUS STRAIN;

EID: 0038122773     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50267     Document Type: Article

References (23)

1. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998;29:198-206.
2. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. HEPATOLOGY 1997;25:735-739.
3. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, Mentha G, Spahr L, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype. J Hepatol 2000;33:106-115.
4. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes. Genotype-specific reversal of hepatic steatosis after sustained response to antiviral therapy. HEPATOLOGY 2002;36:1266-1272.
5. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouillères O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001;34:428-434.
6. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. HEPATOLOGY 2001;33:1358-1364.
7. Gerber MA, Krawczynski K, Alter MJ, Sampliner RE, Margolis HS. Histopathology of community acquired chronic hepatitis C. Mod Pathol 1992;5:483-486.
8. Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr, Balart LA, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastroenterology 1993;104:595-603.
9. Bach N, Thung SN, Schaffner R. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. HEPATOLOGY 1992;15:572-577.
10. Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, Negro F. Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology 2001;39:119-124.
11. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. HEPATOLOGY 2002;36:729-736.
12. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. PEG-Interferon alfa-2b in combination with ribavirin compared to interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Lancet 2001;358:958-965.
13. The METAVIR Cooperative Group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. HEPATOLOGY 1994;20:15-20.
14. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996;24:289-293.
15. Tong MJ, Hwang SJ, Lefkowitz M, Lee SD, Co RL, Conrad A, Schmid P, et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. J Gastroenterol Hepatol 1994;9:587-591.
16. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. HEPATOLOGY 2000;32:654-659.
17. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterisation of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-1102.
18. Hintze JL. NCSS 97 User Guide. Number Cruncher Statistical Systems. Kaysville, UT, 1997.
19. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura T, Eder G, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997;94:1200-1205.
20. Bjoro K, Bell H, Hellum KB, Skaug K, Raknerud N, Sandvei P, Doskeland B, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002;37:226-232.
21. Akuta N, Suzuki F, Tsubota A, Suzuki Y, Someya T, Kobayashi M, Saitoh S, et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 2002;37:831-836.
22. Lewis JA, Huq A, Najarro P. Inhibition of mitochondrial function by interferon. J Biol Chem 1996;22:13184-13190.
23. Fromenty B, Berson A, Pessayre D. Microvesicular steatosis and steatohepatitis: role of mitochondrial dysfunction and lipid peroxydation. J Hepatol 1997;26:13-22.